Clinical use of aspirin in treatment and prevention of cardiovascular disease.

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-24 DOI:10.1155/2012/245037
Yuxiang Dai, Junbo Ge
{"title":"Clinical use of aspirin in treatment and prevention of cardiovascular disease.","authors":"Yuxiang Dai,&nbsp;Junbo Ge","doi":"10.1155/2012/245037","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"245037"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/245037","citationCount":"71","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2012/245037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/11/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 71

Abstract

Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿司匹林在治疗和预防心血管疾病中的临床应用。
心血管疾病,主要是心脏病和中风,是发达国家男性和女性死亡的主要原因。阿司匹林是CVD中应用最广泛和试验最多的抗血小板药物,在不同人群的临床试验中被证明是抗血小板治疗和预防CVD的基石。在急性冠状动脉综合征、血栓性中风和川崎病中,急性使用阿司匹林可以降低死亡率和心血管事件的复发率。作为二级预防,阿司匹林被认为对急性冠状动脉综合征、稳定型心绞痛、血运重建术、中风、TIA和房颤有效。阿司匹林也可用于未来心血管疾病高风险患者的一级预防,但必须考虑益处和可能的副作用之间的平衡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pathogenesis of Thromboembolism and Endovascular Management Referral Patterns and Diagnostic Yield of Lung Scintigraphy in the Diagnosis of Acute Pulmonary Embolism. miR-19a and miR-20a and Tissue Factor Expression in Activated Human Peripheral Blood Mononuclear Cells. Medicinal Herbals with Antiplatelet Properties Benefit in Coronary Atherothrombotic Diseases The Incidence of Peripheral Catheter-Related Thrombosis in Surgical Patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1